Why clinical translation cannot succeed without failure
The high rates of attrition that occur in drug development are widely regarded as problematic, but the failure of well-designed studies benefits both researchers and healthcare systems by, for example, generating evidence about disease theories and demonstrating the limits of proven drugs. A wider r...
Main Authors: | Alex John London, Jonathan Kimmelman |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2015-11-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/12844 |
Similar Items
-
Is preclinical research in cancer biology reproducible enough?
by: Patrick Bodilly Kane, et al.
Published: (2021-12-01) -
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles
by: Attila A. Seyhan
Published: (2019-11-01) -
Facilitating translational team science: The project leader model
by: Lynn Sutton, et al.
Published: (2019-08-01) -
Translational medicine: ways of development in modern conditions, problems and prospects
by: Oksana Bobrova, et al.
Published: (2022-07-01) -
The proportion of randomized controlled trials that inform clinical practice
by: Nora Hutchinson, et al.
Published: (2022-08-01)